A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

“Our findings confirm this (already established) knowledge, but also show that the cardiovascular benefits of SGLT2 inhibitors are even greater in older compared to younger people, despite the ...

Experts are now calling for NHS guidance - which does not recommend managing diabetes with different drugs depending on age - ...

A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...